These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 18821084)
1. Levodopa-induced dyskinesias and their management. Del Sorbo F; Albanese A J Neurol; 2008 Aug; 255 Suppl 4():32-41. PubMed ID: 18821084 [TBL] [Abstract][Full Text] [Related]
2. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Krack P; Pollak P; Limousin P; Benazzouz A; Deuschl G; Benabid AL Brain; 1999 Jun; 122 ( Pt 6)():1133-46. PubMed ID: 10356065 [TBL] [Abstract][Full Text] [Related]
3. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Rodriguez-Oroz MC; López-Azcárate J; Garcia-Garcia D; Alegre M; Toledo J; Valencia M; Guridi J; Artieda J; Obeso JA Brain; 2011 Jan; 134(Pt 1):36-49. PubMed ID: 21059746 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies to prevent motor complications in Parkinson's disease. Kieburtz K J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085 [TBL] [Abstract][Full Text] [Related]
5. Immediate and sustained relief of levodopa-induced dyskinesias after dorsal relocation of a deep brain stimulation lead. Case report. Alterman RL; Shils JL; Gudesblatt M; Tagliati M Neurosurg Focus; 2004 Jul; 17(1):E6. PubMed ID: 15264775 [TBL] [Abstract][Full Text] [Related]
6. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. Alonso-Frech F; Zamarbide I; Alegre M; Rodríguez-Oroz MC; Guridi J; Manrique M; Valencia M; Artieda J; Obeso JA Brain; 2006 Jul; 129(Pt 7):1748-57. PubMed ID: 16684788 [TBL] [Abstract][Full Text] [Related]
7. The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias. Cerasa A; Donzuso G; Morelli M; Mangone G; Salsone M; Passamonti L; Augimeri A; Arabia G; Quattrone A Mov Disord; 2015 Dec; 30(14):1912-20. PubMed ID: 26275050 [TBL] [Abstract][Full Text] [Related]
8. Dyskinesias and the subthalamic nucleus. Benabid AL; Benazzouz A; Limousin P; Koudsie A; Krack P; Piallat B; Pollak P Ann Neurol; 2000 Apr; 47(4 Suppl 1):S189-92. PubMed ID: 10762147 [TBL] [Abstract][Full Text] [Related]
9. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959 [TBL] [Abstract][Full Text] [Related]
10. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias. Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805 [TBL] [Abstract][Full Text] [Related]
11. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601 [TBL] [Abstract][Full Text] [Related]
12. Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias. Follett KA Neurosurg Focus; 2004 Jul; 17(1):E3. PubMed ID: 15264772 [TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Encarnacion EV; Hauser RA Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609 [TBL] [Abstract][Full Text] [Related]
14. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Cilia R; Akpalu A; Sarfo FS; Cham M; Amboni M; Cereda E; Fabbri M; Adjei P; Akassi J; Bonetti A; Pezzoli G Brain; 2014 Oct; 137(Pt 10):2731-42. PubMed ID: 25034897 [TBL] [Abstract][Full Text] [Related]
15. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500 [TBL] [Abstract][Full Text] [Related]
16. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. Zesiewicz TA; Sullivan KL; Hauser RA Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536 [TBL] [Abstract][Full Text] [Related]
17. Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. Merello M; Perez-Lloret S; Antico J; Obeso JA J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):172-4. PubMed ID: 16421117 [TBL] [Abstract][Full Text] [Related]
18. Role of surgery in the treatment of motor complications. Metman LV; O'Leary ST Mov Disord; 2005; 20 Suppl 11():S45-56. PubMed ID: 15822076 [TBL] [Abstract][Full Text] [Related]
19. [Dyskinesia caused by L-DOPA]. Derkinderen P; Vidailhet M Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668 [TBL] [Abstract][Full Text] [Related]
20. Dyskinesias and grip control in Parkinson's disease are normalized by chronic stimulation of the subthalamic nucleus. Wenzelburger R; Zhang BR; Poepping M; Schrader B; Müller D; Kopper F; Fietzek U; Mehdorn HM; Deuschl G; Krack P Ann Neurol; 2002 Aug; 52(2):240-3. PubMed ID: 12210799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]